Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Spekulatius who wrote (22355)	6/16/1998 10:53:00 PM
From: Hippieslayer	Respond to of 32384

What everyone's take on what will happen tomorrow? Will the pied piper lead the rats away or will we continue to get infested?

To: Spekulatius who wrote (22355)	6/17/1998 3:00:00 AM
From: scaram(o)uche	Respond to of 32384

Ralf: I own a bunch of second- and third-tier biotechs that have been getting hammered just like LGND. I've resorted to trading on news; while that's been very successful and countered my rotting long-term portfolio, I try to accumulate the issues without drawing too much attention to them. Given this, I think I'd be foolish to give a list of favorites. I did, in response to a similar question a few days ago, ask Peter Suzman and Jim Silverman to add to a list of those that looked "cheap". The three of us had substantial overlap, and came up with a long list of companies without too much effort. Some comments..... "Anyone picking OSIP? GENE? ARIA? ARQL? ABSC? (ugh, yech), AXPH?, PCOP?, xxxx?, SIBI?, LGND?, xxxx?, VGINF?, KDUS?, fill in the blank??" "Amongst others: I like ARQL, PGNS, MLNM (FYI Lander has sold his last shares--I believe), PDLI, KDUS, ARIA, XNVAY, SIBI, NSTK, GELX, INCY, SNAP, OSIP, AXPH, xxxx is interesting (more insider buying)." "ARQL, AXPH, PCOP, LGND, VGINF. I'd suggest PCYC if low twenties are allowed. If we're going for real cheapies, why not NTII? CBMI." But, then, here's Peter's disclaimer, which was echoed by Jim and which I also proclaim....... "My trouble with all of these is, although I personally own small amounts of a few of them, I'd feel awfully funny recommending them to anyone else. Cheap biotechs are not exactly market favorites right now, and I suspect its going to be a while before things turn around." Cheers! Rick